Detail akcie Acrux online

Business Summary: Acrux Limited is a drug development company. The Company is engaged in developing and commercializing branded and generic transdermal and topical pharmaceuticals for global markets. The Company's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The Company's products include Axiron, Ellavie, Evamist and Lenzetto. Axiron (testosterone) topical solution CIII is a testosterone topical solution approved for application via an armpit (underarm) applicator. It has developed the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause. In the United States, the Company's estradiol spray is branded Evamist. The Company has licensed its estradiol product to Gedeon Richter to commercialize in various territories, including Europe and Eurasia. Gedeon Richter has branded the estradiol spray as Lenzetto.
Financial Summary: BRIEF: For the six months ended 31 December 2019, Acrux Limited revenues decreased 78% to A$576K. Net loss increased 85% to A$6.5M. Revenues reflect Australia segment decrease of 94% to A$140K. Higher net loss reflects External research and development expens increase of 27% to A$2.4M (expense), Depreciation and amortisation expense increase of 65% to A$346K (expense).